NASDAQ:AAPG Ascentage Pharma Group International (AAPG) Stock Price, News & Analysis $47.90 +0.21 (+0.44%) As of 08/22/2025 03:32 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Ascentage Pharma Group International Stock (NASDAQ:AAPG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AAPG alerts:Sign Up Key Stats Today's Range$47.20▼$48.4550-Day Range$31.64▼$47.9052-Week Range$16.50▼$48.45Volume6,948 shsAverage Volume8,133 shsMarket Capitalization$4.45 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company Overview Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China. Read More Receive AAPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascentage Pharma Group International and its competitors with MarketBeat's FREE daily newsletter. Email Address AAPG Stock News HeadlinesASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business UpdatesAugust 21 at 8:19 AM | finanznachrichten.deAscentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business UpdatesAugust 20, 2025 | globenewswire.comTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed professionals, retirees, and high-net-worth savers. But the wealthy aren’t just writing checks. They’re moving fast to protect capital and purchasing power using legal, IRS-compliant strategies. American Alternative Assets just released the Mar-A-Lago Accord, a free guide revealing how to reduce Q3 tax exposure and reposition wealth before it’s drained.August 24 at 2:00 AM | American Alternative (Ad)Ascentage Pharma’s Lisaftoclax Phase III Trial for HR-MDS Cleared by FDA and EMAAugust 18, 2025 | msn.comAscentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMAAugust 17, 2025 | globenewswire.comJ.P. Morgan Sticks to Their Buy Rating for Ascentage Pharma Group International Unsponsored ADR (AAPG)August 12, 2025 | theglobeandmail.comAscentage Pharma to Announce 2025 Interim Results and Corporate UpdateAugust 12, 2025 | theglobeandmail.comAscentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025August 7, 2025 | globenewswire.comSee More Headlines AAPG Stock Analysis - Frequently Asked Questions How have AAPG shares performed this year? Ascentage Pharma Group International's stock was trading at $18.67 at the start of the year. Since then, AAPG stock has increased by 156.6% and is now trading at $47.90. When did Ascentage Pharma Group International IPO? Ascentage Pharma Group International (AAPG) raised $126 million in an initial public offering (IPO) on Friday, January 24th 2025. The company issued 7,325,000 shares at a price of $17.25 per share. When did the company's lock-up period expire? Ascentage Pharma Group International's lock-up period expired on Wednesday, July 23rd. Ascentage Pharma Group International had issued 7,325,000 shares in its IPO on January 24th. The total size of the offering was $126,356,250 based on an initial share price of $17.25. Since the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted. Who are Ascentage Pharma Group International's major shareholders? Top institutional shareholders of Ascentage Pharma Group International include Tema Etfs LLC (0.02%), Hsbc Holdings PLC (0.01%) and Chevy Chase Trust Holdings LLC (0.01%). How do I buy shares of Ascentage Pharma Group International? Shares of AAPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today8/24/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AAPG Previous SymbolNASDAQ:AAPG CIK2023311 WebN/A Phone86 512 8555 7777FaxN/AEmployees600Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio3.24 Current Ratio1.26 Quick Ratio1.26 Sales & Book Value Annual Sales$134.35 million Price / Sales33.14 Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book99.79Miscellaneous Outstanding Shares92,960,000Free FloatN/AMarket Cap$4.45 billion OptionableN/A BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:AAPG) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascentage Pharma Group International - Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascentage Pharma Group International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.